Jump Financial LLC Makes New Investment in Zura Bio Limited (NASDAQ:ZURA)

Jump Financial LLC acquired a new stake in Zura Bio Limited (NASDAQ:ZURA) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 23,701 shares of the company’s stock, valued at approximately $59,000.

A number of other institutional investors have also recently made changes to their positions in ZURA. American Century Companies Inc. acquired a new stake in Zura Bio during the 4th quarter worth approximately $27,000. Prudential Financial Inc. acquired a new stake in Zura Bio during the 4th quarter worth approximately $28,000. XTX Topco Ltd acquired a new stake in Zura Bio during the 4th quarter worth approximately $44,000. SG Americas Securities LLC lifted its holdings in Zura Bio by 51.6% during the 4th quarter. SG Americas Securities LLC now owns 23,005 shares of the company’s stock worth $58,000 after buying an additional 7,828 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in Zura Bio by 68.6% during the 4th quarter. Wells Fargo & Company MN now owns 23,053 shares of the company’s stock worth $58,000 after buying an additional 9,379 shares in the last quarter. Institutional investors and hedge funds own 61.14% of the company’s stock.

Zura Bio Price Performance

NASDAQ ZURA opened at $1.41 on Tuesday. The firm’s fifty day moving average price is $1.27 and its 200 day moving average price is $2.28. The company has a market capitalization of $96.41 million, a price-to-earnings ratio of -2.66 and a beta of 0.08. Zura Bio Limited has a 12 month low of $0.97 and a 12 month high of $6.35.

Zura Bio (NASDAQ:ZURA) last issued its quarterly earnings data on Tuesday, March 25th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.09. The business had revenue of $0.00 million for the quarter. As a group, sell-side analysts forecast that Zura Bio Limited will post -0.65 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. HC Wainwright reiterated a “buy” rating on shares of Zura Bio in a report on Thursday, April 3rd. Oppenheimer reissued an “outperform” rating and issued a $19.00 price objective (down from $20.00) on shares of Zura Bio in a research report on Wednesday, March 26th. Chardan Capital dropped their price objective on shares of Zura Bio from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, March 26th. Finally, Guggenheim reissued a “buy” rating and issued a $15.00 price objective on shares of Zura Bio in a research report on Wednesday, March 26th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Zura Bio currently has an average rating of “Buy” and a consensus target price of $14.67.

Zura Bio Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.